Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months ...Leggi tutto